239 related articles for article (PubMed ID: 33120989)
1. Relationship of 2D Affinity to T Cell Functional Outcomes.
Kolawole EM; Lamb TJ; Evavold BD
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33120989
[TBL] [Abstract][Full Text] [Related]
2. The kinetics of two-dimensional TCR and pMHC interactions determine T-cell responsiveness.
Huang J; Zarnitsyna VI; Liu B; Edwards LJ; Jiang N; Evavold BD; Zhu C
Nature; 2010 Apr; 464(7290):932-6. PubMed ID: 20357766
[TBL] [Abstract][Full Text] [Related]
3. TCR binding kinetics measured with MHC class I tetramers reveal a positive selecting peptide with relatively high affinity for TCR.
Holmberg K; Mariathasan S; Ohteki T; Ohashi PS; Gascoigne NR
J Immunol; 2003 Sep; 171(5):2427-34. PubMed ID: 12928390
[TBL] [Abstract][Full Text] [Related]
4. Is TCR/pMHC Affinity a Good Estimate of the T-cell Response? An Answer Based on Predictions From 12 Phenotypic Models.
Gálvez J; Gálvez JJ; García-Peñarrubia P
Front Immunol; 2019; 10():349. PubMed ID: 30886616
[TBL] [Abstract][Full Text] [Related]
5. Modulation of T cell function by TCR/pMHC binding kinetics.
Carreño LJ; González PA; Kalergis AM
Immunobiology; 2006; 211(1-2):47-64. PubMed ID: 16446170
[TBL] [Abstract][Full Text] [Related]
6. The cellular environment regulates in situ kinetics of T-cell receptor interaction with peptide major histocompatibility complex.
Liu B; Chen W; Natarajan K; Li Z; Margulies DH; Zhu C
Eur J Immunol; 2015 Jul; 45(7):2099-110. PubMed ID: 25944482
[TBL] [Abstract][Full Text] [Related]
7. Dissecting TCR-MHC/peptide complex interactions with A2/peptide multimers incorporating tumor antigen peptide variants: crucial role of interaction kinetics on functional outcomes.
Dutoit V; Guillaume P; Cerottini JC; Romero P; Valmori D
Eur J Immunol; 2002 Nov; 32(11):3285-93. PubMed ID: 12555674
[TBL] [Abstract][Full Text] [Related]
8. Normalized Synergy Predicts That CD8 Co-Receptor Contribution to T Cell Receptor (TCR) and pMHC Binding Decreases As TCR Affinity Increases in Human Viral-Specific T Cells.
Williams CM; Schonnesen AA; Zhang SQ; Ma KY; He C; Yamamoto T; Eckhardt SG; Klebanoff CA; Jiang N
Front Immunol; 2017; 8():894. PubMed ID: 28804489
[TBL] [Abstract][Full Text] [Related]
9. Monitoring the Dynamics of T Cell Clonal Diversity Using Recombinant Peptide:MHC Technology.
Blanchfield JL; Shorter SK; Evavold BD
Front Immunol; 2013; 4():170. PubMed ID: 23840195
[TBL] [Abstract][Full Text] [Related]
10. What's the Catch? The Significance of Catch Bonds in T Cell Activation.
Faust MA; Rasé VJ; Lamb TJ; Evavold BD
J Immunol; 2023 Aug; 211(3):333-342. PubMed ID: 37459191
[TBL] [Abstract][Full Text] [Related]
11. Antibody stabilization of peptide-MHC multimers reveals functional T cells bearing extremely low-affinity TCRs.
Tungatt K; Bianchi V; Crowther MD; Powell WE; Schauenburg AJ; Trimby A; Donia M; Miles JJ; Holland CJ; Cole DK; Godkin AJ; Peakman M; Straten PT; Svane IM; Sewell AK; Dolton G
J Immunol; 2015 Jan; 194(1):463-74. PubMed ID: 25452566
[TBL] [Abstract][Full Text] [Related]
12. Quantitative TCR:pMHC Dissociation Rate Assessment by NTAmers Reveals Antimelanoma T Cell Repertoires Enriched for High Functional Competence.
Gannon PO; Wieckowski S; Baumgaertner P; Hebeisen M; Allard M; Speiser DE; Rufer N
J Immunol; 2015 Jul; 195(1):356-66. PubMed ID: 26002978
[TBL] [Abstract][Full Text] [Related]
13. The Quest for the Best: How TCR Affinity, Avidity, and Functional Avidity Affect TCR-Engineered T-Cell Antitumor Responses.
Campillo-Davo D; Flumens D; Lion E
Cells; 2020 Jul; 9(7):. PubMed ID: 32708366
[TBL] [Abstract][Full Text] [Related]
14. Time required for commitment to T cell proliferation depends on TCR affinity and cytokine response.
Wu LZ; Balyan R; Brzostek J; Zhao X; Gascoigne NRJ
EMBO Rep; 2023 Jan; 24(1):e54969. PubMed ID: 36327141
[TBL] [Abstract][Full Text] [Related]
15. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
16. T-cell receptor triggering is critically dependent on the dimensions of its peptide-MHC ligand.
Choudhuri K; Wiseman D; Brown MH; Gould K; van der Merwe PA
Nature; 2005 Jul; 436(7050):578-82. PubMed ID: 16049493
[TBL] [Abstract][Full Text] [Related]
17. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
18. Peptide-MHC Class I Tetramers Can Fail To Detect Relevant Functional T Cell Clonotypes and Underestimate Antigen-Reactive T Cell Populations.
Rius C; Attaf M; Tungatt K; Bianchi V; Legut M; Bovay A; Donia M; Thor Straten P; Peakman M; Svane IM; Ott S; Connor T; Szomolay B; Dolton G; Sewell AK
J Immunol; 2018 Apr; 200(7):2263-2279. PubMed ID: 29483360
[TBL] [Abstract][Full Text] [Related]
19. Force-Regulated In Situ TCR-Peptide-Bound MHC Class II Kinetics Determine Functions of CD4+ T Cells.
Hong J; Persaud SP; Horvath S; Allen PM; Evavold BD; Zhu C
J Immunol; 2015 Oct; 195(8):3557-64. PubMed ID: 26336148
[TBL] [Abstract][Full Text] [Related]
20. Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines.
McMahan RH; McWilliams JA; Jordan KR; Dow SW; Wilson DB; Slansky JE
J Clin Invest; 2006 Sep; 116(9):2543-51. PubMed ID: 16932807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
